Clinical Trial Update: A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

View source ↗

Summary

A clinical trial update reporting completion of a study evaluating apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate | Status: COMPLETED